34 filings · most recent first
HALO 8-K Filings
Halozyme Therapeutics Announces Sale Of 15 Billion Convertible Senior Notes
Halozyme Announces Merger With Elektrofi
Halozyme Therapeutics Announces Acquisition Of Elektrofi To Expand Drug
Halozyme Therapeutics Appoints Dannielle Appelhans To Board Of Directors
Halozyme Reports Record Q2 2026 Results And Raises Fullyear Guidance
Halozyme Therapeutics Announces Departure Of Coo
Halozyme Announces New 1 Billion Share Repurchase Program And Reports Q1 2026
Halozyme Therapeutics Holds Annual Meeting Of Stockholders
Halozyme Appoints New Chief Financial Officer
Halozyme Therapeutics Amends Bylaws To Revise Director Removal And Meeting
Halozyme Therapeutics Appoints David Ramsay As Interim Cfo
Halozyme Therapeutics Reports Record Revenue And Reiterates 2026 Financial
Halozyme Therapeutics Updates 2026 Financial Guidance And Announces Surf Bio
Halozyme Therapeutics Approves Performancebased Stock Grant For Ceo
Halozyme Therapeutics Elects New Board Member
Halozyme Therapeutics Cfo Departure
Halozyme Therapeutics Announces Pricing Of 13 Billion Convertible Notes Offering
Halozyme Therapeutics Announces Credit Agreement Amendment And Convertible
Halozyme Reports Strong Q3 2025 Financial Results And Announces Cfo Transition
Halozyme Provides Statement On Cms Medicare Price Negotiation Guidance
Halozyme Therapeutics Appoints New Chief Operating Officer
Halozyme Therapeutics Raises 2025 Financial Guidance And Reports Strong Q2 2025
Halozyme Reports Strong Q1 2025 Results And Raises Financial Guidance
Halozyme Therapeutics Holds Annual Meeting With Key Votes Passed
Halozyme Therapeutics Announces Cto Retirement
Halozyme Therapeutics Reports Strong 2024 Financial Results And Reiterates 2025
Board Member Connie L Matsui Not Standing For Reelection
Halozyme Raises 2025 And Multiyear Financial Guidance Announces 250M Share
Halozyme Reports Strong Q3 2024 Results And Raises Fullyear Guidance
Halozyme Therapeutics Reports Strong Q2 2024 Financial Results
Halozyme Reports Q1 2024 Financial Results And Announces New 750M Share
Halozyme Therapeutics Inc Announces Successful Annual Meeting And Director
Halozyme Reports Q4 2023 Financial Results And Announces New 750M Share
Halozyme Therapeutics Provides Preliminary 2023 Financial Estimates